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ProspectiveAbstract Aim: MERiDiAN evaluated plasma vascular endothelial growth factor-A
(pVEGF-A) prospectively as a predictive biomarker for bevacizumab efficacy in metastatic
breast cancer (mBC).
Methods: In this double-blind placebo-controlled randomised phase III trial, eligible patients
had HER2-negative mBC previously untreated with chemotherapy. pVEGF-A was measured
before randomisation to paclitaxel 90 mg/m2 on days 1, 8 and 15 with either placebo or bev-
acizumab 10 mg/kg on days 1 and 15, repeated every 4 weeks until disease progression, unac-
ceptable toxicity or consent withdrawal. Stratification factors were baseline pVEGF-A, prior
adjuvant chemotherapy, hormone receptor status and geographic region. Co-primary end-
points were investigator-assessed progression-free survival (PFS) in the intent-to-treat and
pVEGF-Ahigh populations.
Results: Of 481 patients randomised (242 placeboepaclitaxel; 239 bevacizumabepaclitaxel),
471 received study treatment. The stratified PFS hazard ratio was 0.68 (99% confidence inter-
val, 0.51e0.91; log-rank p Z 0.0007) in the intent-to-treat population (median 8.8 months
with placeboepaclitaxel versus 11.0 months with bevacizumabepaclitaxel) and 0.64 (96% con-
fidence interval, 0.47e0.88; log-rank p Z 0.0038) in the pVEGF-Ahigh subgroup. The PFS
treatment-by-VEGF-A interaction p value (secondary end-point) was 0.4619. Bevacizumab
was associated with increased incidences of bleeding (all grades: 45% versus 27% with pla-
cebo), neutropenia (all grades: 39% versus 29%; grade 3: 25% versus 13%) and hypertension
(all grades: 31% versus 13%; grade 3: 11% versus 4%).
Conclusion: The significant PFS improvement with bevacizumab is consistent with previous
placebo-controlled first-line trials in mBC. Results do not support using baseline pVEGF-A
to identify patients benefitting most from bevacizumab.
Clinical trials registration: ClinicalTrials.gov NCT01663727.
ª 2016 Published by Elsevier Ltd.1. Introduction
In three randomised phase III trials, adding bev-
acizumab to first-line chemotherapy for HER2-negative
metastatic breast cancer (mBC) significantly improved
progression-free survival (PFS) and overall response
rate, but not overall survival (OS) [1e3]. Regulatory
approval of bevacizumab in mBC was based on the
open-label randomised phase III E2100 trial, which
demonstrated median PFS of 11.3 months with bev-
acizumabepaclitaxel versus 5.8 months with paclitaxel
alone (hazard ratio [HR] 0.48) [4]. In two subsequent
randomised phase III trials combining bevacizumab
with alternative chemotherapies, PFS HRs were more
modest [2,3]. Possible explanations for this apparent
difference include synergistic anti-angiogenic activity of
weekly paclitaxel and bevacizumab [5] and methodo-
logical differences between the trials. The open-label
design and unblinded investigator assessment of PFS
in E2100 attracted criticism, although retrospectiveIndependent Review Facility (IRF)-assessed PFS
showed similar results [4].
Numerous post hoc retrospective subgroup analyses
according to clinical and disease characteristics suggest
that no specific subgroup derives substantially greater
benefit from bevacizumab [6]. Following reassessment of
available bevacizumab data, a post-approval commit-
ment was made to the European health authorities to
continue attempts to identify a predictive biomarker for
bevacizumab efficacy in mBC.
As angiogenesis is a highly complex process, the bev-
acizumab biomarker programme included a range of
candidate biomarkers involved in known pathways of
angiogenesis, tumorigenesis and activation of alternative
pathways. Following extensive exploration of various
sample types across multiple trials and tumour entities,
plasmavascular endothelial growth factor (pVEGF)-Awas
considered the most promising candidate biomarker [7,8].
Initial analyses in lung, colorectal and renal cancers iden-
tifiedaprognosticbut notpredictive effectof pVEGF-A [9].
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HER2-negative mBC, gastric and pancreatic cancers using
a novel immunologic multi-parameter chip technology
(IMPACT) enzyme-linked immunosorbent assay sug-
gested potential predictive and prognostic effects of pre-
treatment pVEGF-A in bevacizumab-treated patients
[10e12]. The randomised phase III MERiDiAN trial was
designed to investigate pVEGF-A prospectively as a pre-
dictive biomarker for bevacizumab effect on PFS in mBC.2. Methods
2.1. Study design
This double-blind placebo-controlled two-arm rando-
mised phase III trial (ClinicalTrials.gov, NCT01663727)
was conducted at 132 centres in the United States of
America, Ukraine, Japan, Russia, Korea, United
Kingdom,Republic ofPanama,Romania,Belgium,South
Africa, Argentina, Bulgaria, Italy, Chile and Germany.
Each participating institution’s Institutional Review
Board or Ethics Committee provided ethical approval.2.2. Patients
Eligible patients had locally assessed HER2-negative
locally recurrent or mBC (LR/mBC) and Eastern Coop-
erative Oncology Group performance status 2. Key
exclusion criteria were: prior chemotherapy for LR/mBC;
prior hormonal therapy<2 weeks before randomisation;
prior (neo)adjuvant chemotherapy <12 months before
randomisation; prior VEGF pathway-targeted therapy;
New York Heart Association Class 2 congestive heart
failure; left ventricular ejection fraction<55%; history of
myocardial infarction, stroke or transient ischaemic
attack within 6 months before randomisation; persistent
grade 3 sensory neuropathy; baseline neutrophil count
<1.5  109/L; or known central nervous system disease.
Patients with treated brain metastases were eligible if they
had no evidence of disease progression (PD) or haemor-
rhage after treatment, no ongoing corticosteroid
requirement and >3 months had elapsed since local
therapy. Additional bevacizumab-specific exclusion
criteria included: inadequately controlled hypertension;
significant vascular disease; proteinuria at screening;
previous hypertensive crisis or hypertensive encephalop-
athy; history of abdominal fistula or gastrointestinal
perforation within 6 months before randomisation; or
major surgical procedure within 28 d before random-
isation. All patients provided written informed consent.
Before randomisation, pVEGF-A was measured in
all patients using an IMPACT assay (version 7.01;
Appendix Table A1). Baseline pVEGF-A level was used
to classify patients as VEGF-Ahigh (5.05 pg/mL) or
VEGF-Alow (<5.05 pg/mL). The 5.05 pg/mL cut-off
represents the median pVEGF-A concentration inretrospective biomarker analyses of AVADO (Appendix
Fig. A1) [10].
Patients were randomly assigned (1:1) to receive first-
line paclitaxel with either placebo or bevacizumab,
stratified by: baseline pVEGF-A concentration (<5.05
versus 5.05 pg/mL); prior adjuvant chemotherapy (yes
versus no); progesterone and oestrogen receptor status
(either or both positive versus both negative); and
geographic region (Asia versus North America/Europe
versus other).
2.3. Procedures
Patients received intravenous paclitaxel 90 mg/m2 on
days 1, 8 and 15 with either placebo or bevacizumab
10 mg/kg intravenously on days 1 and 15, all repeated
every 4 weeks until PD, unacceptable toxicity or with-
drawal of consent. If one drug was discontinued for any
reason except PD, the remaining agent could be
continued until PD, unacceptable toxicity or withdrawal
of consent. Investigators assessed tumours by physical
examination and computed tomography, magnetic
resonance imaging or nuclear bone scans using
Response Evaluation Criteria in Solid Tumours
(RECIST; version 1.1) every 8 weeks until PD, regard-
less of whether the patient remained on study treatment.
Survival follow-up and post-progression cancer therapy
data were collected every 3 months until death, loss to
follow-up or study termination. Adverse events (AEs)
were recorded at every cycle.
An IRF reviewed scans and patient materials at
regular intervals throughout the study. PFS according
to IRF assessment was a prespecified sensitivity analysis.
2.4. Outcomes
The co-primary end-points were investigator-assessed
PFS in the intent-to-treat (ITT) population and
investigator-assessed PFS in the pVEGF-Ahigh sub-
group. PFS was defined as the interval between ran-
domisation and first recorded PD (or death, if earlier).
Secondary end-points were: VEGF-A-by-treatment
interaction test for PFS in the ITT population;
investigator-assessed objective response rate (ORR) in
patients with measurable disease at baseline (RECIST
version 1.1); duration of objective response in
responding patients with measurable disease at base-
line; OS; 1-year OS rate; and safety (treatment-emer-
gent AEs graded using National Cancer Institute
Common Terminology Criteria for Adverse Events,
version 4.0).
2.5. Statistical analysis
It was planned to randomise approximately 480 patients.
The primary PFS analysis was prespecified after PFS
events had been recorded both in 326 patients in the ITT
Fig. 1. Trial profile.
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HR of 0.67 (median PFS increase from 8 to 12 months)
at a 1% significance level, and in 146 patients in the
pVEGF-Ahigh population, which allowed 85% power to
detect a HR of 0.60 (median PFS increase from 6 to 10
months) at a 4% significance level. PFS was compared
between treatment groups using two-sided stratified log-
rank tests.
Efficacy analyses were performed on all randomised
patients within the relevant populations (ITT or
pVEGF-Ahigh). Safety was analysed in all patients who
received at least one dose of study medication. SAS
(version 9.2; SAS Institute Inc., Cary, NC, USA) was
used for all statistical analyses.
The final OS analysis will occur after deaths in
approximately 309 patients in the ITT population and
approximately 170 patients in the VEGF-Ahigh sub-
group. An interim OS analysis was conducted at the
time of the primary PFS analysis; however, as the pre-
specified number of OS events had not occurred, a sec-
ond interim OS analysis was conducted after this
number was reached.
An independent Data Monitoring Committee regu-
larly reviewed the unblinded safety data to monitor
overall patient safety.3. Results
Between 27 August 2012 and 26 December 2013, 481
patients were randomised (Fig. 1), of whom 471 received
at least one dose of study treatment. Baseline charac-
teristics were generally balanced between treatment
groups (Table 1). The median baseline pVEGF-A con-
centration in the pooled population was 5.27 pg/mL
(range, 0.5e90.5 pg/mL). Baseline characteristics ac-
cording to baseline pVEGF-A level are shown in
Appendix Table A2.
At the data cut-off date for the primary PFS analysis
(30 November 2014), 13% of the patients in the place-
boepaclitaxel group and 16% in the bev-
acizumabepaclitaxel group remained on study treatment.
In both treatment groups, the median duration of pla-
cebo/bevacizumab treatment was slightly longer
(approximately 1 month) than that of paclitaxel and some
patients continued single-agent therapy (with either pla-
cebo/bevacizumab or paclitaxel) for several months
(Table 2). In both treatment groups the reasons for dis-
continuing paclitaxel and discontinuing placebo/bev-
acizumab were generally similar, except for a slightly
increased proportion discontinuing paclitaxel because of
AEs and a correspondingly slightly decreased proportion
Table 1
Baseline characteristics.
Characteristic Placeboepaclitaxel (n Z 242) Bevacizumabepaclitaxel (n Z 239)
Age, years
Median (range) 56 (28e77) 55 (28e85)
Age group, years, n (%)
<40 21 (8.7) 17 (7.1)
40 to 64 175 (72.3) 165 (69.0)
65 46 (19.0) 57 (23.8)
Region, n (%)
Asia 45 (18.6) 47 (19.7)
North America/Europe 111 (45.9) 108 (45.2)
Other 86 (35.5) 84 (35.1)
ECOG PS, n (%)
0 141 (58.5) 123 (51.5)
1 100 (41.5) 116 (48.5)
Missing 1 0
Median baseline plasma VEGF-A level, pg/mL (range) 5.31 (0.5e90.5) 5.24 (0.9e66.2)
Hormone receptor status, n (%)
ER and/or PgR positive 203 (83.9) 200 (83.7)
ER and PgR negative 39 (16.1) 39 (16.3)
Measurable disease at baseline 214 (88.4) 202 (84.5)
No. of metastatic sites, n (%)
<3 112 (46.3) 117 (49.0)
3 130 (53.7) 122 (51.0)
Previous adjuvant chemotherapy, n (%) 118 (48.8) 116 (48.5)
Previous (neoadjuvant or adjuvant) taxane therapy, n (%) 76 (31.4) 81 (33.9)
Previous (neoadjuvant or adjuvant) anthracycline therapy, n (%) 125 (51.7) 115 (48.1)
Previous adjuvant hormonal therapy, n (%) 105 (43.4) 92 (38.5)
Previous hormonal therapy for LR/mBC, n (%) 42 (17.4) 38 (15.9)
Disease-free interval, months, n (%)
0 79 (32.6) 68 (28.5)
>0 to 24 88 (36.4) 80 (33.5)
>24 75 (31.0) 91 (38.1)
ECOG PS Z Eastern Cooperative Oncology Group performance status; ER Z oestrogen receptor; LR/mBC Z locally recurrent or metastatic
breast cancer; PgR Z progesterone receptor; VEGF-A Z vascular endothelial growth factor-A.
Table 2
Treatment exposure.
Treatment exposure Placeboepaclitaxel (n Z 233) Bevacizumabepaclitaxel (n Z 238)
Median number of cycles (range)
Paclitaxel 6 (1e28) 7 (1e28)
Bevacizumab/placebo 7.5 (1e28) 8 (1e24)
Mean number of cycles
Paclitaxel 8.1 8.5
Bevacizumab/placebo 8.6 8.8
Median duration, months (range)
Paclitaxel 5.2 (<0.1e25.3) 5.9 (<0.1e25.5)
Bevacizumab/placebo 6.4 (<0.1e25.3) 6.9 (<0.1e21.6)
Median cumulative dose (range), mg/kg
Paclitaxel 2720 (3e15,770) 2907 (135e12,557)
Bevacizumab/placebo 9644 (420e55,880) 9598 (520e35,360)
Mean dose intensity, % (SD)
Paclitaxel 92.7 (12.7) 89.0 (14.6)
Bevacizumab/placeboa 105.5 (17.5) 103.3 (19.2)
Paclitaxel continued for 1 year, n (%) 40 (17.2) 51 (21.4)
Patients continuing single-agent bevacizumab/placebo after
discontinuing paclitaxel, n (%)
31 (13.3) 39 (16.4)
Mean duration of single-agent bevacizumab/placebo, months (SD) 4.3 (3.2) 4.0 (3.3)
Patients continuing single-agent paclitaxel after discontinuing
bevacizumab/placebo, n (%)
11 (4.7) 24 (10.1)
Mean duration of single-agent paclitaxel, months (SD) 4.7 (5.6) 3.7 (5.3)
SD Z standard deviation.
a Calculated as actual dose in mg divided by planned dose in mg at the time of randomisation. Although bevacizumab dose changes were not
permitted according to the protocol, in a few cases, doses were recalculated according to weight changes, resulting in dose intensities exceeding
100%.
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mental arm (Appendix Table A3).
At the primary PFS analysis, the median duration of
follow-up for efficacy was 14.8 and 15.0 months in the
placeboepaclitaxel and bevacizumabepaclitaxel
groups, respectively.
Both co-primary objectives were met (Fig. 2). In the
ITT population, the stratified PFS HR was 0.68 (99%
confidence interval [CI], 0.51e0.91; log-rank pZ 0.0007).
Median PFS was 8.8 months with placeboepaclitaxel
and 11.0 months with bevacizumabepaclitaxel. In the
VEGF-Ahigh subgroup, the stratified PFS HR was 0.64
(96% CI, 0.47e0.88; log-rank pZ 0.0038). Median PFSFig. 2. Investigator-assessed progression-free survival: (A) intent-to-t
subgroupdthe 96% CI reflects 4% alpha. HR Z hazard ratio; VEGFwas 7.3 months with placeboepaclitaxel and 9.6 months
with bevacizumabepaclitaxel.
Results of the sensitivity analysis of IRF-assessed PFS
supported the investigator-assessed PFS results (strati-
fied HR 0.68; 95% CI, 0.53e0.88). Median PFS was 9.7
(95% CI, 7.8e11.3) months in the placeboepaclitaxel
group versus 12.9 (95% CI, 11.1e14.4) months in the
bevacizumabepaclitaxel group (Appendix Fig. A2). An
additional sensitivity analysis censoring for non-protocol
therapy before PD was consistent with findings from the
primary analysis (stratified HR 0.61; 95% CI, 0.48e0.78).
The effect of bevacizumab on PFS was consistent across
all subgroups analysed (Fig. 3).reat populationdthe 99% CI reflects 1% alpha; (B) VEGF-Ahigh
-A Z vascular endothelial growth factor-A.
Fig. 3. Subgroup analysis of investigator-assessed PFS. aStratified analysis, Wald confidence interval. ECOG PS Z Eastern Cooperative
Oncology Group performance status; PFS Z progression-free survival.
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(p Z 0.4619) for PFS in the ITT population did not
support a predictive effect of pVEGF-A (Fig. 4).
The ORR was 33.2% (95% CI, 26.9%e39.5%) in the
placeboepaclitaxel group versus 54.0% (95% CI, 47.1%e
60.8%) in the bevacizumabepaclitaxel group (p< 0.0001).
The median duration of response in responding patients
was 9.2 (95% CI, 7.4e11.5) versus 9.5 (95% CI, 7.8e12.4)
months, respectively. OS data are immature; the second
interim OS analysis after deaths in 196 patients (41%)
showed no significant difference between treatment arms
(Fig. 5). Appendix Table A4 summarises post-progression
therapy.Fig. 4. Investigator-assessed PFS according to baseline pVEGF-A leve
and ER/PgR status. bStratified by prior adjuvant chemotherapy and
PFS Z progression-free survival; PgR Z progesterone receptor; pVEThe most common all-grade AEs were alopecia,
nausea, epistaxis and peripheral sensory neuropathy
with bevacizumabepaclitaxel and alopecia and periph-
eral sensory neuropathy with placeboepaclitaxel
(Appendix Table A5). Bevacizumab was associated with
higher incidences of all-grade bleeding, neutropenia and
associated complications (all grades and grade 3) and
hypertension (all grades and grade 3; Table 3).
All but six deaths in each treatment group were due
to PD. In the placeboepaclitaxel group, there were two
deaths from dyspnoea, one from pneumonia, one sud-
den death, one hip fracture and one unexplained death
(on day 278 after one cycle of study therapy). In thel. aStratified by prior adjuvant chemotherapy, baseline pVEGF-A
ER/PgR status. ER Z oestrogen receptor; ITT Z intent-to-treat;
GF-A Z plasma vascular endothelial growth factor-A.
Fig. 5. Overall survival (data cut-off 31 July 2015; median OS follow-up: 20.2 months in the placeboepaclitaxel arm versus 20.7 months in
the bevacizumabepaclitaxel arm). aStratified by prior adjuvant chemotherapy, baseline pVEGF-A and oestrogen/progesterone receptor
status. NE Z not evaluable; pVEGF-A Z plasma vascular endothelial growth factor-A.
Table 3
Summary of adverse events of special interest.






Bleeding 62 (26.6) 106 (44.5)
Grade 3 2 (0.9) 2 (0.8)
Neutropenia and associated
complications
68 (29.2) 92 (38.7)
Grade 3 30 (12.9) 59 (24.8)
Febrile neutropenia 1 (0.4) 5 (2.1)
Hypertension 31 (13.3) 74 (31.1)
Grade 3 10 (4.3) 26 (10.9)
Proteinuria 26 (11.2) 25 (10.5)
Grade 3 1 (0.4) 1 (0.4)
Venous thromboembolic events 11 (4.7) 11 (4.6)
Grade 3 3 (1.3) 9 (3.8)a
Arterial thromboembolic events 5 (2.1) 4 (1.7)
Grade 3 0 0
Wound-healing complication 0 7 (2.9)
Grade 3 0 1 (0.4)
Gastrointestinal perforation 0 5 (2.1)
Grade 3 0 3 (1.3)b
Congestive heart failure 2 (0.9) 3 (1.3)
Grade 3 1 (0.4) 1 (0.4)
a Pulmonary embolism in 7 patients.
b Abdominal wall abscess, colonic abscess and peritonitis (each
n Z 1).
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from hepatic failure, one from hyperbilirubinaemia, one
from sepsis and two unexplained deaths (on days 11 and
94, respectively, after one cycle of study therapy).
AEs led to discontinuation of any study treatment
(paclitaxel, placebo or bevacizumab) in 23% of patients
receiving placeboepaclitaxel and 32% receiving bev-
acizumabepaclitaxel. Placebo or bevacizumab were
discontinued because of AEs in 10% of patients
receiving placeboepaclitaxel and 22% receivingbevacizumabepaclitaxel (most commonly due to hy-
pertension [2.5%], peripheral neuropathy [1.7%] and
peripheral sensory neuropathy [1.7%]). Paclitaxel was
discontinued because of AEs in 22% of the patients
receiving placeboepaclitaxel versus 29% receiving bev-
acizumabepaclitaxel, the predominant AEs being ner-
vous system disorders including peripheral sensory
neuropathy in 5% and 6%, respectively.
4. Discussion
The MERiDiAN trial met both of its co-primary ob-
jectives, demonstrating a significant improvement in
PFS with the addition of bevacizumab to paclitaxel in
both the ITT and the pVEGF-Ahigh populations. Me-
dian PFS with bevacizumabepaclitaxel was consistent
with previously reported randomised phase III trials
evaluating this regimen (11.0 months in MERiDiAN,
11.4 months in E2100 [4], 11.0 months in CALGB 40502
[13] and TURANDOT [14]). The 8.8-month median
PFS with weekly paclitaxel in MERiDiAN was longer
than in the open-label E2100 trial and two earlier studies
(median 5e6 months) [15,16] but similar to more recent
randomised trials [17,18]. In MERiDiAN, the observed
HR met the target HR specified in the trial design and is
consistent with previous first-line placebo-controlled
trials of bevacizumab in mBC [2,3]. The magnitude of
bevacizumab effect on PFS (measured by HR) was less
pronounced in MERiDiAN than E2100.
The median baseline pVEGF-A concentration in
MERiDiAN (5.27 pg/mL in the pooled population) was
similar to the 5.05 pg/mL cut-off from AVADO [10] used
to stratify patients at randomisation in MERiDiAN.
Therefore the VEGF-Ahigh and VEGF-Alow subgroups in
MERiDiAN were of almost equal size. As in several
D. Miles et al. / European Journal of Cancer 70 (2017) 146e155154previous analyses [9e12], patients with high pVEGF-A
levels appeared to have a worse prognosis than those
with low levels, as indicated by the higher event rate and
shorter median PFS in both treatment arms for the
VEGF-Ahigh versus VEGF-Alow subgroups. There was no
evidence of a predictive effect of baseline pVEGF-A level
(PFS VEGF-A-by-treatment interaction pZ 0.4619).
MERiDiAN is the first trial prospectively evaluating
a candidate biomarker for bevacizumab efficacy, repre-
senting a major strength over previous retrospective
biomarker analyses [7,9e12,19,20]. With the given
sample size, the data do not support pVEGF-A as a
predictive marker. This may be because of a true lack of
effect or an effect that is too weak to be of clinical
utility. Given the complexity and multifactorial nature
of the underlying angiogenic mechanisms, it is perhaps
unrealistic to expect a single biomarker to predict benefit
from anti-VEGF therapy. Further analyses undertaken
since the MERiDiAN trial was designed did not support
a straightforward relationship between pVEGF-A and
bevacizumab efficacy. The potential predictive effect of
pVEGF-A suggested in AVADO, AViTA and AVA-
GAST [10e12] was not replicated in retrospective ana-
lyses of nine further trials in various tumour types [19].
Furthermore, in reassessment of available samples from
the AVADO trial using a different version of the assay,
the potential predictive effect of pVEGF-A levels was
not statistically significant [19,21]. Collectively, available
data suggest a low likelihood of pVEGF-A predicting
bevacizumab efficacy. Despite an extensive search for a
biomarker for bevacizumab efficacy and mandatory
biomarker sampling in MERiDiAN, there is no evidence
suggesting that factors other than clinical reasons
should influence patient selection for bevacizumab.
The secondary efficacy end-point of ORR and
sensitivity analyses of PFS supported the primary end-
point results. Final OS results are anticipated in 2017.
The tolerability of bevacizumabepaclitaxel in ME-
RiDiAN was consistent with the established safety pro-
file of bevacizumab-containing therapy for mBC [1e3].
Bevacizumab was associated with increased incidences of
bleeding, neutropenia and hypertension but discontinu-
ations for these AEs were uncommon. Furthermore,
consistent with a published meta-analysis [22], incidences
of arterial thromboembolic events and fatal events were
not increased with bevacizumab-containing therapy. The
incidence of grade 3 AEs classified as gastrointestinal
perforation appeared slightly higher with bevacizumab-
containing therapy, but this classification grouped
together a broad range of AEs, including abdominal wall
abscess, colonic abscess and peritonitis (each of which
occurred in one patient receiving bev-
acizumabepaclitaxel). There were more patients with
grade 3 venous thromboembolic events in the bev-
acizumab arm than in the placebo arm (nine versus three,
respectively), the major contributing event being pul-
monary embolism in seven bevacizumab-treated patients.In conclusion, the significant PFS benefit from adding
bevacizumab to paclitaxel is consistent with previous first-
line placebo-controlled trials of bevacizumab in mBC.
MERiDiAN results did not support baseline pVEGF-A
as a predictive marker for bevacizumab PFS benefit.
Based on these findings and previous retrospective ana-
lyses, pVEGF-A does not appear to identify patients
deriving the most substantial benefit from bevacizumab.
In the overall MERiDiAN population, median PFS with
bevacizumabepaclitaxel replicates that in three previous
randomised phase III trials evaluating this combination.
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